BiotechTV - News - TopPodcast.com

Latest Episodes:

10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform Apr 19, 2026

Show notes

Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted assays, and has single-cell level sensitivity.

Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated Apr 17, 2026

Show notes

Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian.

Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers Apr 14, 2026

Show notes

He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics.

Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year Apr 14, 2026

Show notes

After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalophy, and new alpha-1 program. The company recently closed a $85 private placement.

Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data Apr 14, 2026

Show notes

He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.

Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept Apr 14, 2026

Show notes

He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date.

Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs Apr 14, 2026

Show notes

He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio.

Raymond James Biotech Innovation Symposium: Wave Life Sciences CEO Paul Bolno discusses the recent INHBE data and previews alpha-1 antitrypsin deficiency data being presented next month Apr 14, 2026

Show notes

He discusses the INHBE data and the market reaction to it, which he believes is due to misconceptions about the patient population, and the next steps for this program. Plus, an AATD presentation that will happen next month at American Thoracic Society.

Raymond James Biotech Innovation Symposium: Tectonic Therapeutic develops biologics against GPCR targets - and is making headway on an unmet need for pulmonary hypertension in heart failure patients Apr 14, 2026

Show notes

CEO Alice Reicin walks us through recent data and guides for what is next in this patient population. Plus, an upcoming healthily volunteer readout for a HHT program and how it might translate to patients in future trials.

Raymond James Biotech Innovation Symposium: Eupraxia has a novel extended release platform for - with data already out and more on the way later this year, Eosinophilic Esophagitis has been a good PoC Apr 14, 2026

Show notes

CEO James Helliwell describes Eupraxia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected